Back to search results

Study of NNC6989-0001 for Overweight or Obesity

This study is testing a new medicine called NNC6989-0001 to see if it is safe and well-tolerated in healthy people who are overweight or have obesity. You could be eligible if you are between 18 and 55 years old and have a Body Mass Index (BMI) of 25.0 to 34.9 kg/m² (for Part A) or 25.0 to 39.9 kg/m² (for Part B). Participants will receive either NNC6989-0001 or a placebo (an inactive substance that looks like the study drug), chosen by chance. The main goal is to track any side effects. This study aims to enroll 96 participants and its current status is unclear.

Study design
This is an interventional study with 96 planned participants. You will be randomly assigned to receive either NNC6989-0001 or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Side effects will be monitored from the time of dosing on Day 1 until the end of study visit, which is Day 7 for Part A and Day 14 for Part B.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07437079

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

Recruiting
PHASE1Ages 18–55InterventionalTreatment
Novo Nordisk A/S
~132 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:NNC6989-0001Placebo (NNC6989-0001)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of treatment emergent adverse events (TEAE) - Part A
Measured over From time of dosing on Day1 until completion of the end of study visit (Day 7)
+2 more outcomes measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female of non-childbearing potential.
Age 18-55 years (both inclusive) at the time of signing the informed consent.
Body mass index (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg/m\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg/m\^2 for Part B (MAD part) and Part C (meal timing and potentially meal composition).
Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion

Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.
Treatment with any GLP-1 RA or a medication with GLP-1 activity within 90 days before screening
Use of prescription or non-prescription medicinal products within 14 days before screening. This includes over the counter medicines such as laxatives, mineral oil, and fat-blocking supplements. Routine multivitamin/mineral supplements at labelled daily doses are permitted; other non-prescription supplements (e.g., high-dose vitamins, weight-loss supplements) are not permitted. Occasional use of over-the-counter acetaminophen or NSAIDs at their labelled doses for mild pain is permitted.

What this trial measures

  • Number of treatment emergent adverse events (TEAE) - Part AFrom time of dosing on Day1 until completion of the end of study visit (Day 7)

    Measure in number of events.

  • Number of treatment emergent adverse events (TEAE) - Part BFrom time of dosing on Day 1 until completion of the end of study visit (Day 14)

    Measured in number of events

  • iAUCTG; The incremental area under the blood triglycerides concentration-time curve following meal test - Part CFollowing meal test at Day -1, Day 1, Day 7 and Day 13

    Measured in ratio